Follow-on Compounds

About Abivax

Abivax is a clinical-stage biotech focused on developing first-in-class oral therapies that modulate the immune system via microRNA-124 enhancement. Its lead asset, obefazimod, has demonstrated positive Phase 3 induction results in ulcerative colitis, positioning it as a potential novel therapeutic with a unique mechanism. The company's strategy leverages its proprietary platform to expand into other inflammatory indications like Crohn's disease while exploring follow-on compounds from its chemical library. With a public listing on Euronext Paris and a valuation over $8B, Abivax is approaching key clinical and regulatory milestones that could validate its platform and drive future growth.

Therapeutic Areas

Other Inflammatory Diseases Drugs